Daewoong Bio Launches 'Omega-3 High-Purity Refined' Eicosa Soft Capsules

Daewoong Bio announced on the 19th that it has launched Icosapent Soft Capsules 300mg, which are highly purified eicosapentaenoic acid (EPA), one of the omega-3 components.

Daewoong Bio's Eicosa Soft Capsules
Photo by Daewoong Bio

The main ingredient of Icosapent Soft Capsules, icosapent ethyl, has been approved by the U.S. Food and Drug Administration (FDA) as a treatment to prevent and reduce the risk of cardiovascular diseases caused by hypertriglyceridemia. Icosapent ethyl drug therapy is considered for patients with hypertriglyceridemia whose triglyceride levels remain above 200 mg/dL even after primary treatment with statin-class drugs for dyslipidemia. However, EPA single-ingredient prescription drugs have only been launched in the U.S. and Europe, so domestic cardiovascular patients have not had the opportunity to be prescribed such treatments until now.

The Icosapent Soft Capsules newly launched by Daewoong Bio are the first high-purity, high-dose EPA single-ingredient product in Korea, and through this, it is expected to provide various treatment options for domestic cardiovascular patients. The capsules also greatly improve patient convenience. Existing omega-3 products often have large tablet sizes and a distinctive fishy smell, which many patients dislike, but Icosapent Soft Capsules have significantly reduced both the tablet size and fishy odor.

The indications for Icosapent Soft Capsules are ▲ improvement of ulcers, pain, and cold sensation caused by occlusive arteriosclerosis ▲ hyperlipidemia.

A Daewoong Bio official said, “There was a limitation in treatment options because there were no EPA single-ingredient prescription drugs in Korea, and some patients did not prefer existing omega-3 products due to the fishy smell. We hope that Icosapent Soft Capsules will establish themselves as an optimal treatment option for many patients.”

This content was produced with the assistance of AI translation services.